Cheng-Chia Lee1,2, Daniel M Trifiletti3, Arjun Sahgal4, Antonio DeSalles5, Laura Fariselli6, Motohiro Hayashi7, Marc Levivier8, Lijun Ma9, Roberto Martínez Álvarez10, Ian Paddick11, Jean Regis12, Samuel Ryu13, Ben Slotman14, Jason Sheehan15. 1. Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China. 2. School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia. 4. Department of Radiation Oncology, University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada. 5. Department of Neurosurgery, University of California Los Angeles, Los Angeles, California. 6. Radiotherapy unit, Radiosurgery dep Istituto neurologico Carlo Besta Foundation, Milan, Italy. 7. Department of Neurosurgery, Tokyo Women's Medical University, Toyko, Japan. 8. Neurosurgery Service and Gamma Knife Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 9. Division Physics, Department of Radiation Oncology, University of California San Francisco, San Francisco, California. 10. Department of Radiosurgery and Functional Neurosurgery, Ruber International Hospital, Madrid, Spain. 11. Division Physics, National Hospital for Neurology and Neurosurgery, London, UK. 12. Department of Functional Neurosurgery, Timone University Hospital, Aix-Marseille University, Marseille, France. 13. Department of Radiation Oncology, Stony Brook University, Stony Brook, New York. 14. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. 15. Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA.
Abstract
BACKGROUND: Stereotactic radiosurgery (SRS) has become popular as a standard treatment for cavernous sinus (CS) meningiomas. OBJECTIVE: To summarize the published literature specific to the treatment of CS meningioma with SRS found through a systematic review, and to create recommendations on behalf of the International Stereotactic Radiosurgery Society. METHODS: Articles published from January 1963 to December 2014 were systemically reviewed. Three electronic databases, PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials, were searched. Publications in English with at least 10 patients (each arm) were included. RESULTS: Of 569 screened abstracts, a total of 49 full-text articles were included in the analysis. All studies were retrospective. Most of the reports had favorable outcomes with 5-yr progression-free survival (PFS) rates ranging from 86% to 99%, and 10-yr PFS rates ranging from 69% to 97%. The post-SRS neurological preservation rate ranged from 80% to 100%. Resection can be considered for the treatment of larger (>3 cm in diameter) and symptomatic CS meningioma in patients both receptive to and medically eligible for open surgery. Adjuvant or salvage SRS for residual or recurrent tumor can be utilized depending on factors such as tumor volume and proximity to adjacent critical organs at risk. CONCLUSION: The literature is limited to level III evidence with respect to outcomes of SRS in patients with CS meningioma. Based on the observed results, SRS offers a favorable benefit to risk profile for patients with CS meningioma.
BACKGROUND: Stereotactic radiosurgery (SRS) has become popular as a standard treatment for cavernous sinus (CS) meningiomas. OBJECTIVE: To summarize the published literature specific to the treatment of CS meningioma with SRS found through a systematic review, and to create recommendations on behalf of the International Stereotactic Radiosurgery Society. METHODS: Articles published from January 1963 to December 2014 were systemically reviewed. Three electronic databases, PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials, were searched. Publications in English with at least 10 patients (each arm) were included. RESULTS: Of 569 screened abstracts, a total of 49 full-text articles were included in the analysis. All studies were retrospective. Most of the reports had favorable outcomes with 5-yr progression-free survival (PFS) rates ranging from 86% to 99%, and 10-yr PFS rates ranging from 69% to 97%. The post-SRS neurological preservation rate ranged from 80% to 100%. Resection can be considered for the treatment of larger (>3 cm in diameter) and symptomatic CS meningioma in patients both receptive to and medically eligible for open surgery. Adjuvant or salvage SRS for residual or recurrent tumor can be utilized depending on factors such as tumor volume and proximity to adjacent critical organs at risk. CONCLUSION: The literature is limited to level III evidence with respect to outcomes of SRS in patients with CS meningioma. Based on the observed results, SRS offers a favorable benefit to risk profile for patients with CS meningioma.
Authors: Alexey S Tokarev; Viacheslav A Rak; Olga L Evdokimova; Valentin N Stepanov; Greg V Koynash; Olga A Viktorova; Artur V Kistenev Journal: J Radiosurg SBRT Date: 2020
Authors: Daniel Rueß; Fenja Fritsche; Stefan Grau; Harald Treuer; Mauritius Hoevels; Martin Kocher; Christian Baues; Maximilian I Ruge Journal: J Neurol Surg B Skull Base Date: 2019-03-12
Authors: D Starnoni; C Tuleasca; L Giammattei; G Cossu; M Bruneau; M Berhouma; J F Cornelius; L Cavallo; S Froelich; E Jouanneau; T R Meling; D Paraskevopoulos; H Schroeder; M Tatagiba; I Zazpe; A Sufianov; M E Sughrue; Ari G Chacko; V Benes; P González-Lopez; Pierre-Hugues Roche; Marc Levivier; Mahmoud Messerer; Roy T Daniel Journal: Acta Neurochir (Wien) Date: 2021-08-16 Impact factor: 2.216
Authors: Marcello Marchetti; Arjun Sahgal; Antonio A F De Salles; Marc Levivier; Lijun Ma; Ian Paddick; Bruce E Pollock; Jean Regis; Jason Sheehan; John H Suh; Shoji Yomo; Laura Fariselli Journal: Neurosurgery Date: 2020-10-15 Impact factor: 4.654